%0 Journal Article
%T 1047. Global Surveillance: Susceptibility of Ceftolozane¨CTazobactam Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected From Bloodstream Infections in the United States From 2015 to 2017
%J Archive of "Open Forum Infectious Diseases".
%D 2018
%R 10.1093/ofid/ofy210.884
%X Ceftolozane¨Ctazobactam (C-T) is an antibacterial combination of a novel antipseudomonal cephalosporin and a ¦Â-lactamase inhibitor. C-T was approved by the US Food and Drug Administration in 2014 and by the European Medicines Agency in 2015 to treat complicated urinary tract infections, acute pyelonephritis, and complicated intra-abdominal infections. The Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) monitors Gram-negative (GN) isolates resistant to C-T worldwide. In the current study, isolates were collected from patients hospitalized with bloodstream infections (BSIs) from 2015 to 2017 within the United States
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255016/